BACKGROUND: Nonadherence to statins limits the benefits of this common drug class. Individual studies assessing predictors of nonadherence have produced inconsistent results. OBJECTIVE: To identify reliable predictors of nonadherence to statins through systematic review and meta-analysis. METHODS: Multiple databases, including MEDLINE, EMBASE, and PsycINFO, were searched (from inception through February 2009) to identify studies that evaluated predictors of nonadherence to statins. Studies were selected using a priori defined criteria, and each study was reviewed by 2 authors who abstracted data on study characteristics and outcomes. Relative risks were then pooled, using an inverse-variance weighted random-effects model. RESULTS: Twenty-two cohort studies met inclusion criteria. Age had a U-shaped association with adherence; the oldest (>/=70 years) and youngest (<50 years) subjects had lower adherence than the middle-aged (50-69 years) subjects. Women and patients with lower incomes were more likely to be nonadherent than were men (odds of nonadherence 1.07; 95% CI 1.04 to 1.11) and those with higher incomes (odds of nonadherence 1.18; 95% CI 1.10 to 1.28), respectively. A history of cardiovascular disease predicted better adherence to statins (odds of nonadherence 0.68; 95% CI 0.66 to 0.78). Similarly, a diagnosis of hypertension or diabetes was associated with better adherence. Although there were too few studies for quantitative pooling, increased testing of lipid levels and lower out-of-pocket costs appeared to be associated with better adherence. There was substantial (I(2) range 68.7-96.3%) heterogeneity between studies across factors. CONCLUSIONS: Several sociodemographic, medical, and health-care utilization characteristics are associated with statin nonadherence. These factors may be useful guides for targeting statin adherence interventions.
BACKGROUND: Nonadherence to statins limits the benefits of this common drug class. Individual studies assessing predictors of nonadherence have produced inconsistent results. OBJECTIVE: To identify reliable predictors of nonadherence to statins through systematic review and meta-analysis. METHODS: Multiple databases, including MEDLINE, EMBASE, and PsycINFO, were searched (from inception through February 2009) to identify studies that evaluated predictors of nonadherence to statins. Studies were selected using a priori defined criteria, and each study was reviewed by 2 authors who abstracted data on study characteristics and outcomes. Relative risks were then pooled, using an inverse-variance weighted random-effects model. RESULTS: Twenty-two cohort studies met inclusion criteria. Age had a U-shaped association with adherence; the oldest (>/=70 years) and youngest (<50 years) subjects had lower adherence than the middle-aged (50-69 years) subjects. Women and patients with lower incomes were more likely to be nonadherent than were men (odds of nonadherence 1.07; 95% CI 1.04 to 1.11) and those with higher incomes (odds of nonadherence 1.18; 95% CI 1.10 to 1.28), respectively. A history of cardiovascular disease predicted better adherence to statins (odds of nonadherence 0.68; 95% CI 0.66 to 0.78). Similarly, a diagnosis of hypertension or diabetes was associated with better adherence. Although there were too few studies for quantitative pooling, increased testing of lipid levels and lower out-of-pocket costs appeared to be associated with better adherence. There was substantial (I(2) range 68.7-96.3%) heterogeneity between studies across factors. CONCLUSIONS: Several sociodemographic, medical, and health-care utilization characteristics are associated with statin nonadherence. These factors may be useful guides for targeting statin adherence interventions.
Authors: Jeppe N Rasmussen; Gunnar H Gislason; Søren Rasmussen; Steen Z Abildstrom; Tina K Schramm; Lars Køber; Finn Diderichsen; Merete Osler; Christian Torp-Pedersen; Mette Madsen Journal: J Epidemiol Community Health Date: 2007-12 Impact factor: 3.710
Authors: Devin M Mann; John P Allegrante; Sundar Natarajan; Ethan A Halm; Mary Charlson Journal: Cardiovasc Drugs Ther Date: 2007-08 Impact factor: 3.727
Authors: Sebastian Schneeweiss; Amanda R Patrick; Malcolm Maclure; Colin R Dormuth; Robert J Glynn Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Jessica M Franklin; William H Shrank; Joyce Lii; Alexis K Krumme; Olga S Matlin; Troyen A Brennan; Niteesh K Choudhry Journal: Health Serv Res Date: 2015-04-16 Impact factor: 3.402
Authors: Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew Journal: Br J Clin Pharmacol Date: 2018-11-08 Impact factor: 4.335
Authors: Devin M Mann; Nicole L Glazer; Michael Winter; Michael K Paasche-Orlow; Paul Muntner; Daichi Shimbo; William G Adams; Nancy R Kressin; Yuqing Zhang; Hyon Choi; Howard Cabral Journal: Am J Cardiol Date: 2013-02-20 Impact factor: 2.778
Authors: Gregory A Phelps; Yanru Qiao; Merrion G Buckley; Junling Wang; Minghui Sam Li; Soumitra S Bhuyan; Marie A Chisholm-Burns Journal: Res Social Adm Pharm Date: 2019-07-25